Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Sanofi and Regeneron have been collaborating since 2003, with the partnership generating some of Sanofi’s most prominent drugs including top-selling Dupixent (dupilumab) for eczema and asthma ...

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has ...

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

Read about Regeneron Pharmaceuticals Inc (REGN:XNAS) stock and today's latest news and financial updates.

Review Regeneron Pharmaceuticals Inc (REGN:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

REGN | Complete Regeneron Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.